Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...
Sanofi targets mid to high single-digit sales growth in 2025 with €5B share buyback plan
Q4 2024 Management View Paul Hudson highlighted significant progress in 2024 towards becoming a focused science-driven ...
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of 10.3% at CER1 and business EPS2 ...
Healio9d
Dupilumab does not desensitize children with peanut allergy
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...
pharmaphorum15d
How patient-on-a-chip tech could be the future of drug discovery
Testing drug compounds on a chip designed to mimic human organs sounds closer to science fiction than reality, yet the technology already exists and is already being put to use. Ben Hargreaves ...
Frontiers17d
Eosinophilic esophagitis in the “atopic march”: dupilumab as an “umbrella” strategy for multiple coexisting atopic diseases
EoE is a chronic T2 inflammatory disease, believed to be a member of the “atopic march”, due to multiple similarities with other atopic diseases, ranging from epidemiology to genetics and ...
Pharmaceutical Technology18d
Etrasimod by Pfizer for Eosinophilic Esophagitis: Likelihood of Approval
Etrasimod is under clinical development by Pfizer and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis have an 80% phase ...
soapcentral20d
EVANGELION:95 apparel collection: Where to get, release date, price, and more explored
In honor of the 30th anniversary of the Japanese anime, Neon Genesis Evangelion, Radio Eva has announced the release of the EVANGELION:95 apparel collection. This is a new line of apparel that will be ...
The Pharma Letter21d
Sanofi to increase competition in atopic dermatitis market after Dupixent’s success
Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...
clinicaltrialsarena21d
Sanofi to increase competition in atopic dermatitis market after Dupixent success
The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...